



Press Release

March 18, 2014

Chiome Bioscience, Inc.

## **Chiome Bioscience Announces Success in Development of a Fully Human ADLib® System**

**Tokyo, Japan – 18 March 2014**

Chiome Bioscience Inc. is delighted to announce that we have successfully constructed a DT40 cell line which meets all required properties for the Fully Human ADLib® library and was verified.

Chiome had announced successful construction of a prototype as a milestone on the way to the Fully Human ADLib® system last June.

We will continue our efforts to construct and select cells which have potential to generate excellent diversity, and build up human libraries that have sufficient diversity equivalent to or greater than the existing ADLib® system for practical use.

Chiome will leverage this major success in our technology development to accelerate making deals with pharmaceutical companies not only in Japan but globally.

Chiome is taking measures to strengthen and secure the IP position of this achievement.

Also we will initiate efforts to realize “Counter-Pandemic infectious diseases” and “Ultimate tailor-made care” to achieve our mission, “A health care innovator that pursues 100% effective treatment”. We will leverage not only relying on our own skills and experiences, but also incorporate external technologies, unique targets, and other party’s knowledge and know-hows to maximize the values of antibodies generated by ADLib® system. By this way, Chiome will strive to deliver services and products that will fulfill patient’s needs, and eventually, will be a well perceived company in the society.

ADLib® is the trademark of Chiome Bioscience.



<About the ADLib<sup>®</sup> system>

The ADLib<sup>®</sup> system is an innovative technology for antibody generation by leveraging gene conversion of chicken DT40 cells. It generates antibodies quite fast, potentially in about 10 days entirely in vitro. Also it generates antibodies with, theoretically, unlimited diversity, which allows for the development of antibodies that have been considered to be difficult by currently available methods. Chiome has also successfully launched libraries that generate directly mouse-chicken IgG antibody from DT40 cells. ADLib<sup>®</sup> is the trademark of Chiome Bioscience.

<About Chiome Bioscience, Inc.>

Chiome is a Japan-based biotech company specialized in antibody and technology development. It has developed an innovative and unique platform technology, ADLib<sup>®</sup> system, to which right Chiome co-owns with RIKEN Institute. Since 2008, it has been engaged in joint research and the generation of antibodies with a number of leading domestic, multinational pharmaceuticals, and diagnostic companies. Chiome offers ADLib<sup>®</sup> system to partners under a non-exclusive license to maximize the value of the technology. By leveraging the proprietary technology Chiome Bioscience believes it can make great contributions in discovery and development of antibody drugs.

CONTACT:

Shigeru Kobayashi Business Development Chiome Bioscience Inc.

E-mail: [antibody@chiome.co.jp](mailto:antibody@chiome.co.jp)